"Characterization of adverse events, health care resource utilization, and real-world survival outcomes with introduction of ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in BC"
"Characterization of adverse events, health care resource utilization, and real-world survival outcomes with introduction of ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) patients in BC"
“通过在不列颠哥伦比亚省的慢性淋巴细胞白血病 (CLL)/小淋巴细胞淋巴瘤 (SLL) 患者中引入依鲁替尼来描述不良事件、医疗保健资源利用和现实世界生存结果”
批准号：
428899
负责人：
Khelifi Rania
金额：
$1.27万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-12-01 至 2020-12-01
中文摘要
翻译
“慢性淋巴细胞白血病（CLL）是西方国家成人中最常见的白血病。已被证明在新诊断的CLL患者和复发患者中非常有效的一种特定药物是伊鲁替尼。然而，伊布替尼会导致cer
英文摘要
"Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in western countries. A particular drug that has proven to be very effective in newly diagnosed CLL patients and those who have relapsed is ibrutinib. Ibrutinib, however, causes cer
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
